List of Excipients in Branded Drug PROAIR RESPICLICK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RPK Pharmaceuticals Inc	PROAIR RESPICLICK	albuterol sulfate	53002-1750	LACTOSE MONOHYDRATE
Teva Respiratory LLC	PROAIR RESPICLICK	albuterol sulfate	59310-580	LACTOSE MONOHYDRATE

ProAir RespiClick Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

ProAir RespiClick is a breath-actuated dry-powder inhaler containing albuterol sulfate, with lactose monohydrate as the principal disclosed excipient. Its commercial differentiation comes less from chemical novelty than from powder engineering, dose-metering, inhaler resistance, airflow independence, and the elimination of propellant. The strongest opportunities are generic or authorized-generic DPI development, lactose and carrier optimization, device-platform licensing, and reformulation for markets that value low global-warming-potential inhalers.

What excipients are used in ProAir RespiClick?

ProAir RespiClick uses lactose monohydrate as the disclosed inactive ingredient. The product does not use hydrofluoroalkane propellant, ethanol, oleic acid, or other common excipients associated with pressurized metered-dose inhalers.

Product attribute	ProAir RespiClick position
Active ingredient	Albuterol sulfate
Delivered dose	90 mcg albuterol base equivalent per actuation
Dosage form	Breath-actuated dry powder inhaler
Principal disclosed excipient	Lactose monohydrate
Device format	Multidose inhaler
Dose count	60 inhalations in the labeled product
Propellant	None
Administration	Breath actuated; no hand-breath coordination required
U.S. application	NDA 207070
Original U.S. approval	2015
Manufacturer	Teva Pharmaceuticals

The FDA label states that each inhalation delivers 108 mcg of albuterol sulfate from the mouthpiece, equivalent to 90 mcg of albuterol base. Lactose functions primarily as a carrier and bulking material, allowing the low-dose albuterol sulfate drug substance to be processed, metered, dispersed, and inhaled consistently.[1]

The product also carries a milk-protein warning because pharmaceutical lactose can contain trace milk proteins. That warning creates a commercial design opportunity for a carrier system that reduces or eliminates milk-derived excipient risk, although the resulting powder must still meet aerodynamic performance and dose-uniformity requirements.

How does lactose function in the ProAir RespiClick formulation?

Lactose is likely used as a carrier to improve powder handling and dose reproducibility. Albuterol sulfate is highly potent relative to the total mass required per dose. A carrier system increases the physical quantity of powder that the inhaler meters and disperses.

The formulation strategy depends on several properties:

• Particle-size distribution of the respirable albuterol fraction
• Lactose carrier size and morphology
• Drug-carrier adhesion
• Powder flow and deagglomeration
• Moisture content and water activity
• Electrostatic charging
• Dose uniformity over the inhaler’s labeled life
• Fine-particle dose and fine-particle fraction
• Resistance to humidity-related aggregation

In a carrier-based DPI, the formulation must balance two opposing requirements. Albuterol particles must adhere strongly enough to the carrier to prevent segregation during handling, but the interaction must be weak enough to release the active drug during inhalation.

Lactose may be engineered through particle-size classification, milling, sieving, spray drying, or surface modification. The commercial value usually resides in the combination of carrier specifications, blending conditions, inhaler geometry, and performance testing rather than in the mere selection of lactose monohydrate.

What formulation patents protect ProAir RespiClick?

The defensible intellectual-property position for ProAir RespiClick is likely distributed across formulation, inhaler-device, dose-metering, airflow, and manufacturing claims. The public product label identifies the product and its NDA, but it does not provide a complete claim-level analysis of the patent estate.

Key patent categories include:

Patent category	Commercial relevance
Dry-powder formulation	Controls drug loading, carrier properties, blending, and aerosolization
Inhaler architecture	Protects dose storage, actuation, airflow channels, and mouthpiece design
Breath-actuation mechanism	Differentiates the product from conventional manually actuated MDIs
Dose metering	Supports consistent delivery across 60 doses
Powder deagglomeration	Determines fine-particle dose and emitted dose
Manufacturing process	May protect blending, filling, assembly, and environmental controls
Combination-product claims	Can cover the drug, formulation, and device as an integrated product

Patent expiration cannot be determined from the FDA label alone. A complete assessment requires the Orange Book patent listing for NDA 207070, relevant continuation and divisional applications, terminal disclaimers, PTA or PTE calculations, and any litigation or settlement records.

The practical freedom-to-operate question is broader than whether a competitor uses lactose. A competing albuterol DPI may avoid a formulation claim but still implicate device, dose-metering, or airflow patents. Conversely, a similar inhaler architecture may be defensible if the competitor changes the carrier system, dose-loading method, or actuation mechanism.

What is the Orange Book status of ProAir RespiClick?

ProAir RespiClick is an FDA-approved prescription drug-device combination product associated with NDA 207070. Its Orange Book significance is that any listed patents may affect generic approval timing and Paragraph IV certification obligations.

A generic applicant seeking approval for an albuterol sulfate DPI could pursue:

1. An abbreviated new drug application referencing ProAir RespiClick.
2. A Paragraph IV certification against listed patents.
3. A Section VIII statement for method-of-use claims, where legally available.
4. A separate 505(b)(2) application if the proposed product differs materially in formulation, device, or clinical use.

The commercial risk is higher for an ANDA that copies the device and powder architecture closely. A product using a distinct device and excipient system may reduce patent exposure but increase development and regulatory complexity.

When does ProAir RespiClick lose exclusivity?

ProAir RespiClick’s FDA regulatory exclusivity is separate from its patent protection. The product was approved in 2015, so any original new-chemical-entity exclusivity period has expired. The continuing barrier is therefore more likely to involve listed patents, device protection, regulatory complexity, and manufacturing know-how rather than remaining NCE exclusivity.

Exclusivity type	Likely status
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	Requires product-specific regulatory review
Listed patent protection	Must be assessed from current Orange Book records
Device and know-how protection	Potentially material even after patent expiry
Generic approval pathway	Potentially available through an ANDA, subject to product-specific requirements

Generic entry timing depends on the applicant’s certification strategy, FDA review, patent litigation, settlement terms, and whether the reference product remains commercially available in the relevant market.

What generic entry risks exist for ProAir RespiClick?

Generic albuterol inhalers already compete with branded ProAir products, but a generic dry-powder equivalent presents different technical barriers from a conventional albuterol HFA inhaler.

The primary development risks are:

Device equivalence

An ANDA applicant must demonstrate that the proposed device delivers the drug consistently and provides equivalent performance. Breath-actuation thresholds, airflow resistance, dose counter behavior, and internal powder handling can be difficult to replicate without infringing device claims or relying on similar manufacturing know-how.

In vitro equivalence

The product must demonstrate comparable delivered dose, aerodynamic particle-size distribution, spray or powder performance, and device operation. For a DPI, fine-particle dose is strongly affected by inhalation flow and formulation-device interaction.

Patient-use performance

A breath-actuated product reduces coordination requirements, but patients must generate sufficient inspiratory flow. Device resistance and airflow requirements affect usability in children, older adults, and patients experiencing acute bronchospasm.

Excipient differences

A competing carrier may improve powder performance but create new regulatory questions involving source, particle-size distribution, moisture sensitivity, and local tolerability. Lactose is widely accepted, which gives it a regulatory advantage over less established carriers.

Intellectual property

The most significant risk may arise from device patents rather than the albuterol molecule. Albuterol sulfate is an old active ingredient, so formulation and device claims carry greater relative importance.

How strong is the ProAir RespiClick patent estate?

The estate is likely strongest where formulation and device claims operate together. A broad claim covering any albuterol sulfate DPI would face validity and prior-art pressure because albuterol DPIs and carrier-based inhalation systems are well established. Narrower claims directed to a particular dose-metering structure, actuation threshold, airflow path, or particle-engineering method may be more commercially useful.

A practical strength assessment should score the estate across five factors:

Factor	Assessment
Active-ingredient exclusivity	Weak; albuterol sulfate is long established
Formulation differentiation	Moderate; carrier and particle engineering may be specific
Device differentiation	Potentially strong if the breath-actuated architecture is narrowly claimed
Manufacturing protection	Potentially important, especially for powder uniformity
Design-around difficulty	Moderate; competitors can change carrier, device, or airflow design

The highest-value claims are those that force a competitor to change several elements at once. A claim limited to lactose alone is easier to design around than a claim combining carrier characteristics with powder dispersion behavior and a defined inhaler geometry.

What commercial opportunities exist in ProAir RespiClick excipient strategy?

Lactose-free or reduced-lactose formulations

A lactose-free carrier could address patients with severe milk-protein allergy and remove the product-specific warning associated with lactose. Candidate systems may include mannitol, trehalose, leucine-containing composites, or engineered spray-dried particles.

The challenge is that an alternative carrier must match lactose in flow, stability, aerosolization, supply reliability, and regulatory familiarity. A lactose-free product would need a clear clinical or commercial benefit to justify the development cost.

Improved humidity stability

Humidity can cause carrier agglomeration, drug migration, and reduced powder dispersibility. Excipient systems with lower hygroscopicity or protective surface coatings could improve shelf life in hot and humid markets.

This opportunity has particular relevance in regions where cold-chain infrastructure is limited and inhalers are exposed to high humidity during transport or household storage.

Low-dose, high-efficiency powders

Improved drug detachment from the carrier can reduce total powder mass while maintaining the delivered albuterol dose. This may permit smaller inhalers, lower excipient consumption, and more consistent performance across inhalation flows.

Sustainable inhaler platforms

Because ProAir RespiClick is propellant-free, its platform has a lower direct propellant burden than HFA-based inhalers. DPI development can therefore support sustainability-oriented procurement and formulary positioning. The environmental claim must still account for device plastics, manufacturing, packaging, and disposal.

Pediatric and low-inspiratory-flow products

A powder system that performs at lower inspiratory flow could expand use in pediatric patients and adults with limited inspiratory capacity. This opportunity depends on device resistance, particle engineering, and robust performance at clinically relevant flow rates.

Combination rescue products

An albuterol DPI platform could support combinations with other bronchodilators or respiratory agents. Combination development would raise dose compatibility, stability, metering, and regulatory complexity. The opportunity is greater where a single device can reduce treatment burden without compromising rescue-dose flexibility.

How does ProAir RespiClick compare with ProAir HFA and ProAir Digihaler?

Product	Dosage form	Propellant	Excipient strategy	Device differentiation
ProAir HFA	Pressurized metered-dose inhaler	HFA-134a	Propellant-based suspension or solution system	Manual actuation and inhalation coordination
ProAir RespiClick	Dry powder inhaler	None	Lactose carrier system	Breath actuated
ProAir Digihaler	Dry powder inhaler with digital functions	None	Dry-powder carrier system	Breath actuation plus electronic dose-use data

ProAir HFA competes through familiarity, broad patient use, and established manufacturing. ProAir RespiClick competes through breath actuation and the absence of propellant. ProAir Digihaler adds a digital component, creating potential value in adherence monitoring and disease management but also adding electronics, software, data, and reimbursement considerations.

For a generic developer, the HFA route may offer larger manufacturing infrastructure, while the RespiClick route may offer differentiation through device usability and a propellant-free format. The DPI pathway can be attractive where environmental policy is shifting away from high-global-warming-potential propellants.

Which companies are positioned to challenge ProAir RespiClick?

Potential competitors include generic manufacturers with respiratory-device capabilities, inhalation contract-development organizations, and companies holding proprietary DPI platforms. The relevant competitive set is not limited to firms that currently market an albuterol DPI.

A credible challenger needs:

• Albuterol sulfate drug-substance supply
• Inhalation-grade lactose or an alternative carrier
• DPI design and human-factors capability
• Cascade impactor and aerosol-performance testing
• Device manufacturing and assembly capacity
• FDA combination-product regulatory expertise
• Freedom to operate across formulation and device claims

The strongest candidates are companies that already manufacture inhaled corticosteroids, long-acting bronchodilators, or other carrier-based DPIs. Generic firms without internal device capabilities may pursue licensing or contract-development arrangements.

What licensing opportunities exist around ProAir RespiClick technology?

Licensing opportunities may arise in four areas:

1. Breath-actuated DPI platforms that can be adapted to albuterol.
2. Carrier-engineering technology that improves fine-particle dose.
3. Lactose-free or low-hygroscopic excipient systems.
4. Device manufacturing, filling, and assembly technology.

A platform owner can license the device separately from the formulation, reducing development cost for generic or regional partners. A formulation owner can retain the powder composition while licensing the inhaler architecture.

Commercial terms would likely depend on territory, regulatory milestones, manufacturing rights, exclusivity, minimum purchase obligations, and ownership of improvements. The most valuable deal structure would align patent life with the expected generic approval and launch period.

What FDA regulatory issues affect a ProAir RespiClick follow-on?

The follow-on product must address the drug, device, and combination-product elements together. FDA review is likely to focus on:

• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Fine-particle dose
• Device robustness
• Dose-counter accuracy
• Actuation reliability
• Performance across humidity and temperature conditions
• Human-factors validation
• Labeling and patient instructions
• Inhalation-flow requirements
• Manufacturing controls for powder blending and filling

A lactose-free formulation may provide a marketing distinction but would not automatically qualify as therapeutically or pharmaceutically equivalent. Excipient changes can affect local deposition, emitted dose, and product performance.

What revenue exposure is associated with ProAir RespiClick?

Revenue exposure is linked to the broader U.S. albuterol rescue market rather than to the active ingredient itself. Albuterol is a high-volume, low-cost product with intense generic competition. The commercial value of ProAir RespiClick is therefore concentrated in:

• Device differentiation
• Brand loyalty
• Formulary placement
• Patient preference
• Propellant-free positioning
• Pharmacy substitution rules
• Availability of an equivalent generic DPI

A generic entrant could pressure pricing quickly if it achieves substitutable device performance. A differentiated lactose-free or low-flow product could support premium pricing, but the premium would require a measurable patient or payer benefit.

Key Takeaways

• ProAir RespiClick uses albuterol sulfate with lactose monohydrate in a breath-actuated DPI.
• Its main commercial protection is likely the integrated powder, metering, airflow, and device system.
• Albuterol’s old active-ingredient status makes formulation and device patents more important than molecule patents.
• The strongest reformulation opportunities are lactose-free carriers, humidity-resistant powders, low-flow performance, and smaller-dose systems.
• Generic entry is technically more difficult than for a conventional albuterol HFA because device equivalence and powder aerosolization must be demonstrated together.
• Patent expiration and Paragraph IV exposure require a current Orange Book and litigation review for NDA 207070.
• The most valuable licensing assets are DPI platforms, carrier-engineering technologies, and manufacturing processes.

FAQs

Can lactose be replaced in a generic ProAir RespiClick formulation?

Yes. Lactose can potentially be replaced with mannitol, trehalose, leucine-containing particles, or another inhalation-grade carrier. The substitute must support equivalent powder flow, dose uniformity, aerosol performance, stability, and regulatory acceptability.

Does ProAir RespiClick contain HFA propellant?

No. ProAir RespiClick is a dry powder inhaler and does not use HFA propellant. Its disclosed carrier excipient is lactose monohydrate.

Is a ProAir RespiClick generic easier to develop than a ProAir HFA generic?

Not necessarily. A DPI avoids propellant formulation issues but creates complex powder-device equivalence requirements. A generic developer must reproduce or design around the breath-actuation and dose-dispersion system.

Can a lactose-free albuterol DPI receive premium pricing?

Potentially, but only if the product demonstrates a meaningful benefit, such as reduced milk-protein exposure, improved humidity stability, better low-flow performance, or a clinically relevant usability advantage.

What is the main manufacturing barrier for an albuterol DPI?

The main barrier is achieving consistent low-dose drug distribution and aerosolization across the full inhaler life. Carrier properties, blending, humidity control, filling, device geometry, and assembly tolerances all affect performance.

References

1. U.S. Food and Drug Administration. (2023). ProAir RespiClick (albuterol sulfate) inhalation powder: Prescribing information. Teva Respiratory, LLC.

2. U.S. Food and Drug Administration. (2015). FDA approves ProAir RespiClick for treatment or prevention of bronchospasm. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Pharmacopeia. (2023). General chapter <601>: Inhalation and nasal drug products: Aerosols, sprays, and powders. U.S. Pharmacopeial Convention.

5. International Council for Harmonisation. (2009). Q8(R2) pharmaceutical development. ICH.

6. European Medicines Agency. (2010). Guideline on the requirements for clinical documentation for orally inhaled products. EMA.